6th AMR Conference
AMR Conference
Thank you to our sponsors, partners and all participants!
Thank you very much
for your participation in the 6th AMR Conference 2022
taking place on 7–8 April at the Congress Center Basel.
We hope you enjoyed the first face-to-face event after two years of virtual meetings and received some successful outcome.
Latest News
in the AMR and antimicrobial space
Vaccines are powerful tools to prevent infections in the first place that could later on lead…
The companies Biomériux, Evotec and Boehringer Ingelheim have joined forces against AMR and announced the launch…
Commonwealth leaders have convened in Kigali, Rwanda, to discuss the challenge of antimicrobial resistance and the…
Increasing cases of antibiotic resistance endanger global health and the availability of modern healthcare. Till date,…
CARB-X (part of Boston University) announces the renewal of its support from Wellcome Trust, a worldwide…
The availability of surveillance data on antimicrobial resistance (AMR) makes it possible to assess incidence rates…
A new study by BD (Becton Dickinson) and MSD (Merck & Co.) found higher rates of…
With the goal of counteracting the growing world-wide crisis over resistance to antibiotics, the United Kingdom…
The recently published report by Boston Consulting Group, prepared together with World Economic Forum, Wellcome Trust,…
6th AMR Conference – What you can expect
The AMR Conference is a platform to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to market.
More than 400 delegates from 25+ countries
80+ high-level speakers in 20 sessions
Pre-conference workshops and satellite meetings
A variety of topics from R&D to financing, regulation & incentives
Poster session, exhibition and pre-scheduled 1:1 partnering meetings
SMEs, academics & governmental agencies benefit from discounted fees
Thanks to all our Supporting Partners of the 6th AMR Conference
2021 Event Highlights
Summer Edition – AMR Briefing Sessions
With around 30 international experts in the line-up, the virtual conference discussed the current state of the fight against antimicrobial resistance (AMR) during three Briefing sessions, which took place from 24 to 26 August under the umbrella of the 5th AMR Conference – Summer Edition.
Almost 500 registered participants took part in the event to follow discussions about pandemic preparedness, the COVID-19 impact on AMR R&D, the financing climate and policy incentives.
Overall, most of the stakeholders emphasised that there is a momentum of optimism. “The level of investment is rising, interest in the field has improved and the overall trend is quite good. Particularly vaccines have found investments”, said Aleks Engel from Novo Holdings REPAIR Impact Fund. Overall, Engel also underlined that there is a lot of innovation taking place in the AMR field: “When we started our fund three years ago, we were embarrassed to see how many innovative companies there are, many more than we could invest in with our fund.” In the meantime, many of them have developed further.
2020 Event Highlights
Event Impressions & Testimonials
The #AMRconference 2020 was a great success. Almost 450 international AMR experts have participated in 26 live sessions which provided a 360 degree overview of the current AMR industry and resulted in engaging discussions.
Did you miss the conference?
Purchase our on-demand license and watch all 20+ sessions and panel discussions whenever you want!
Get your individual licence to access all session recordings, slides and scientific poster presentations of the AMR Conference 2020 here:
2019 Event Highlights
Event Impressions & Testimonials
More than 330 experts joined the 2-day AMR Conference 2019 in Berlin. They called for rapid capital investments and economic incentives in the fight against antimicrobial resistance (AMR). The AMR Conference is a platform for SMEs, start-ups, big pharma, academia, clinicians, investors, public stakeholders and policy-makers to discuss strategies and the specific challenges faced by SMEs in bringing new antimicrobial treatments and diagnostics to the market.
